Urokinase biosimilar - Tasly Pharmaceutical

Drug Profile

Urokinase biosimilar - Tasly Pharmaceutical

Alternative Names: Recombinant human prourokinase; Recombinant human urokinase - Tasly Pharmaceuticals; rhPro-uk - Tasly Pharmaceuticals

Latest Information Update: 08 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tasly Pharmaceuticals, Inc.
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase II Pulmonary embolism

Most Recent Events

  • 09 May 2017 Phase-II clinical trials in Pulmonary embolism in China (IV) (NCT03108833)
  • 17 Apr 2017 Tasly Pharmaceuticals plans the ERUPTE phase II trial for Pulmonary embolism in China (NCT03108833)
  • 21 Nov 2011 Launched for Myocardial infarction in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top